Navigation Links
Discuss Early Results of the DIAN Trial at CBI's 6th Annual Alzheimer's Drug Development Summit
Date:8/21/2012

WOBURN, Mass., Aug. 21, 2012 /PRNewswire/ -- CBI recently added John C. Morris M.D., a Friedman Distinguished Professor of Neurology and Director at Knight Research Center of Washington University School of Medicine, to the prestigious speaker roster for CBI's 6th Annual Alzheimer's Drug Development Summit in Philadelphia.

This December 11-12, attendees come together during the session: Future Perspective from the Dominantly Inherited Alzheimer Network (DIAN) (http://www.cbinet.com/conference/workshop/26087/pc12188) to discuss the early results from the trial as well as review key highlights and information:

  • Analyze the importance of the DIAN trial to Alzheimer's clinical trials
  • Discuss the therapies being evaluated in the DIAN trial and study design
  • Understand the initial results of the DIAN clinical trial and forward goals

With a strong agenda filled with expert speakers reflecting on recent clinical trial implications and current research on translational and preventative treatments for Alzheimer's, CBI's 6th Annual Alzheimer's Drug Development Summit offers industry leaders an educational platform to continue the dialogue of research findings and continue to advance towards the prevention and treatment of Alzheimer's disease.

CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Contact: Kristina Weljkovic
Phone number: 339-298-2285
Email address: Kristina.weljkovic@cbinet.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.  


'/>"/>
SOURCE CBI
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
2. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
3. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
4. Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama
5. NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program"
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Researchers peek at the early evolution of sex chromosomes
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
10. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
11. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):